P134 CAR‑T Cell Therapy for Recurrent Glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open‑label, single‑arm Phase 1/2 trial using dose‑escalation followed by a dose‑expansion cohort to study P134 CD44/CD133 dual‑targeting CAR‑T cells in adults with recurrent IDH‑wildtype glioblastoma. Eligible participants are 18–70 years old with histologically or molecularly confirmed grade 4 IDH‑wildtype glioblastoma and at least one measurable lesion ≤3 cm; prior radiotherapy and/or temozolomide/bevacizumab is required. Patients must be suitable for neurosurgical placement of a CSF access device (e.g., Ommaya reservoir) for cell delivery and CSF sampling. The trial's main goals are to define safety and tolerability, identify the maximum tolerated dose and recommended Phase 2 dose, and characterize CAR‑T cytokinetic profiles in cerebrospinal fluid, with tumor response monitored by RANO criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntary written informed consent.
2. 18-70 years of age (inclusive), male or female.
3. Recurrent or progressive glioblastoma, histopathologically or molecularly diagnosed consistent with grade 4 glioblastoma (IDH wild-type) (refer to WHO Classification of Central Nervous System Tumors, 5th Edition, 2021).
4. Positive CD44 or CD133 antigen expression in tumor tissue confirmed by IHC, defined as ≥1% of tumor cells showing positive CD44 or CD133 IHC staining, regardless of intensity (applicable only in Phase II dose expansion study).
5. At least one measurable lesion meeting RANO 2.0 criteria and having a radiographically assessed measurable lesion ≤ 3 cm in longest diameter
6. Patient has received prior radiation therapy and/or temozolomide/bevacizumab.
7. The investigator confirmed that the patient was suitable for craniotomy cerebrospinal fluid shunt and accessory (Ommaya reservoir) implantation.

Exclusion Criteria:

1. Highly allergic constitution or history of severe allergy, or allergy to related cell products
2. Receipt of biologic anti-tumor therapy (including monoclonal or bispecific antibody-targeted therapy, immune checkpoint inhibitor therapy, etc.) within 6 weeks prior to PBMC collection; receipt of radiotherapy or surgery within 4 weeks prior to PBMC collection (excluding placement of vascular access devices; a 1-week washout period is acceptable for diagnostic biopsy surgeries); receipt of chemotherapy, hormone therapy (excluding hormone replacement therapy), or non-specific immunomodulatory therapy (such as interleukins, interferons, thymosin, cyclophosphamide, methotrexate, tumor necrosis factor, etc.) within 2 weeks prior to PBMC collection; receipt of traditional Chinese medicine therapy with a clear anticancer indication within 1 week prior to PBMC collection.
3. The adverse reactions caused by previous anti-tumor treatment have not recovered to ≤ Grade 1 as evaluated by NCI CTCAE v6.0 (except alopecia, skin pigmentation, leukoplakia, etc. which are assessed as having no safety risk).
4. Tumor metastasis to the brainstem or spinal cord.
5. Suffering from other serious neurological diseases other than brain tumors, such as meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, amyotrophic lateral sclerosis, spinal muscular atrophy, nerve paralysis, uncontrolled epilepsy, etc.
6. Patients with primary immunodeficiency disease, autoimmune diseases requiring medication (such as Crohn 's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus), or previous history of autoimmune diseases of the nervous system (such as multiple sclerosis, Parkinson' s disease).
7. Receiving or requiring long-term use of immunosuppressive agents (except for physiological doses of systemic corticosteroids ≤ 10 mg/day prednisone equivalent, short-term ≤ 7 days corticosteroids for allergies, or topical glucocorticoids).
8. Trial participants who have a previous history of allogeneic bone marrow transplantation or organ transplantation, or are awaiting organ transplantation.
9. HBsAg positive and HBV DNA positive, HCV Ab positive and HCV RNA positive; Treponema pallidum antibody positive; human immunodeficiency virus (HIV) antibody positive.
10. Prior receipt of any gene therapy or cell therapy trial participant.
11. Pregnant or lactating women.
12. History of malignancy other than glioma within 5 years (except for adequately treated carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, localized prostate cancer, or stage I cervical cancer, which in the opinion of the investigator carries a minimal risk of recurrence).

Where it's running

• Beijing Tiantan Hospital, Capital Medical University
  Beijing, China Recruiting

Study contacts

• Principal investigator: Zhang Wei, Prof. — Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R.China
• Study coordinator: Zhang Yuping
• Email: zhangyuping90@taslypharma.com
• Phone: +8615022490519

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• "177Lu" Lu-DOTA-EB-RGD2 Therapy for Recurrent High-Grade Glioma

  This study tests a radiopharmaceutical called Lu-177 DOTA-EB-RGD2 to see if it is safe and tolerable in adults with recurrent high-grade gliomas.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07655869

• Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771

  This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07648823

• Locally delivered EGFR/IL13Rα2 CAR T-cell therapy for recurrent high-grade gliomas

  This phase I study tests whether a patient's own EGFR/IL13Rα2 CAR T cells, given directly into the brain, are safe and can help adults with recurrent or progressive high-grade gliomas.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07544992

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• ERAS-801 for operable or recurrent EGFR-altered IDH-wildtype Grade IV glioblastoma or astrocytoma

  This trial tests ERAS-801, a brain-penetrant EGFR blocker, to see if it is safe and changes tumor metabolism in adults with resectable or recurrent IDH-wildtype Grade IV glioblastoma or astrocytoma that have EGFR amplification or mutation.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California and 1 other locations · NCT07089641

• Adding triapine to radiation therapy for recurrent glioblastoma and astrocytoma

  This early-phase study tests whether giving the drug triapine together with radiation is safe and tolerable for adults whose glioblastoma or astrocytoma has come back.

  Recruiting at 36 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06860594

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.